• If you are wondering whether Ventas at around US$83.27 offers fair value or a potential mismatch between price and fundamentals, this article walks through the key signals to watch.
• The stock has returned 0.7% over the last 7 days, 7.7% year to date and 22.9% over the past year, alongside a 3 year return of 115.3% and a 5 year return of 79.6%, which raises questions about how much optimism is already in the price.
• Recent coverage has focused on Ventas as a major health care REIT, with attention on how it is positioned within senior housing, medical office and related assets. Investors have also been weighing sector wide headlines about interest rates and real estate, using Ventas as a reference point for how the market is pricing health care property exposure.
• On Simply Wall St, Ventas currently records a valuation score of 3 out of 6. The next sections will compare different valuation approaches to see what is already priced in and then finish with a broader way to think about valuation that goes beyond any single metric.

Ventas delivered 22.9% returns over the last year. See how this stacks up to the rest of the Health Care REITs industry.

Approach 1: Ventas Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future adjusted funds from operations and then discounting those cash flows back to today in dollar terms.

For Ventas, the model used is a 2 stage Free Cash Flow to Equity approach based on adjusted funds from operations. The latest twelve month free cash flow is about $1.62b. Analyst sourced and extrapolated projections in the model indicate free cash flow of about $2.35b in 2030, with a series of annual estimates between 2026 and 2035 that are discounted back to present value.

Aggregating these discounted cash flows produces an estimated intrinsic value of around $115.29 per share. Compared with a current share price of about $83.27, this output suggests a 27.8% discount relative to the DCF estimate.

Result: UNDERVALUED (per this model)

Our Discounted Cash Flow (DCF) analysis suggests Ventas is undervalued by 27.8%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Ventas.

Approach 2: Ventas Price vs Sales

For profitable companies, price-based multiples can give a quick sense of how much you are paying for each unit of business performance. For a real estate investment trust, P/S can be useful because it looks at the value the market places on each dollar of revenue, rather than relying only on accounting earnings.

Growth expectations and risk usually influence what counts as a normal or fair P/S ratio. Higher expected growth or perceived resilience can justify a higher multiple, while higher risk or weaker growth tends to be reflected in a lower multiple.

Ventas currently trades on a P/S ratio of 6.80x, compared with an industry average P/S of 6.80x for Health Care REITs and a peer average of 7.44x. Simply Wall St also calculates a proprietary Fair Ratio of 5.78x, which is the P/S level suggested for Ventas after considering factors such as its earnings growth profile, industry, profit margin, market cap and risk characteristics.

This Fair Ratio can be more tailored than a simple comparison against peers or the sector, because it adjusts for those company specific inputs. With the current P/S of 6.80x sitting above the Fair Ratio of 5.78x, the multiple indicates that the shares are priced above that modelled level.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Ventas Narrative

Earlier it was mentioned that there is an even better way to think about valuation, and on Simply Wall St that is through Narratives. You choose the story behind your numbers by linking your view of Ventas, your assumptions for future revenue, earnings and margins, and your own fair value to the current price. This is all available in an easy tool on the Community page that updates as new earnings or news arrive. One investor might build a Narrative close to the higher US$102.00 fair value, another might lean toward the lower US$85.00 view, and both can quickly see whether their chosen fair value makes the current price of about US$82.18 look attractive or stretched.

Do you think there's more to the story for Ventas? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.